NO20013397L - Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer - Google Patents

Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer

Info

Publication number
NO20013397L
NO20013397L NO20013397A NO20013397A NO20013397L NO 20013397 L NO20013397 L NO 20013397L NO 20013397 A NO20013397 A NO 20013397A NO 20013397 A NO20013397 A NO 20013397A NO 20013397 L NO20013397 L NO 20013397L
Authority
NO
Norway
Prior art keywords
auto
apoptosis
treatment
immune disorders
inducing agents
Prior art date
Application number
NO20013397A
Other languages
English (en)
Other versions
NO20013397D0 (no
Inventor
Mathieu Hubertus Mari Noteborn
Alexandra Maria Pietersen
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Publication of NO20013397D0 publication Critical patent/NO20013397D0/no
Publication of NO20013397L publication Critical patent/NO20013397L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO20013397A 1999-01-11 2001-07-09 Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer NO20013397L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200056 1999-01-11
PCT/NL2000/000013 WO2000041497A2 (en) 1999-01-11 2000-01-10 Use of apoptosis inducing agents in the treatment of (auto)immune diseases

Publications (2)

Publication Number Publication Date
NO20013397D0 NO20013397D0 (no) 2001-07-09
NO20013397L true NO20013397L (no) 2001-09-11

Family

ID=8239795

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013397A NO20013397L (no) 1999-01-11 2001-07-09 Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer

Country Status (18)

Country Link
US (1) US20050271624A1 (no)
EP (1) EP1143994B1 (no)
JP (1) JP2003500336A (no)
AT (1) ATE244014T1 (no)
AU (1) AU3083500A (no)
CA (1) CA2359392A1 (no)
DE (1) DE60003632T2 (no)
DK (1) DK1143994T3 (no)
EA (1) EA200100770A1 (no)
ES (1) ES2202039T3 (no)
HU (1) HUP0200552A2 (no)
IL (2) IL144228A0 (no)
MX (1) MXPA01006998A (no)
NO (1) NO20013397L (no)
PT (1) PT1143994E (no)
TR (1) TR200102713T2 (no)
WO (1) WO2000041497A2 (no)
ZA (1) ZA200105632B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002079222A2 (en) * 2001-03-30 2002-10-10 Leadd B.V. Fusion proteins for specific treatment of cancer and auto-immune diseases
US6924266B2 (en) * 2001-05-25 2005-08-02 Nymox Corporation NTP-peptides and method for removal of tumors
PL207588B1 (pl) * 2001-07-19 2011-01-31 Nymox Corp Peptyd NTP, środek zawierający ten peptyd i zastosowanie tego peptydu
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5981502A (en) * 1990-09-12 1999-11-09 Leadd B.V. Methods and compositions for inducing apoptosis in tumor cells
EP0878546A1 (en) * 1997-04-15 1998-11-18 Leadd B.V. A gene delivery vehicle expressing the apoptosis-inducing proteins VP2 and/or apoptin
US5792751A (en) * 1992-04-13 1998-08-11 Baylor College Of Medicine Tranformation of cells associated with fluid spaces
NZ309171A (en) * 1995-06-07 2000-04-28 Leadd Bv use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
DE19704979A1 (de) * 1996-02-07 1997-08-14 Max Delbrueck Centrum Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen
JP2001516210A (ja) * 1997-02-28 2001-09-25 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 遺伝子治療による炎症細胞の自己調節されたアポトーシス
JPH10324699A (ja) * 1997-03-21 1998-12-08 Sankyo Co Ltd 抗ヒトFasヒト化抗体
AU736287B2 (en) * 1997-03-21 2001-07-26 Sankyo Company Limited Humanized anti-human Fas antibody

Also Published As

Publication number Publication date
WO2000041497A2 (en) 2000-07-20
JP2003500336A (ja) 2003-01-07
HUP0200552A2 (en) 2002-06-29
DE60003632D1 (de) 2003-08-07
EA200100770A1 (ru) 2002-02-28
PT1143994E (pt) 2003-11-28
ZA200105632B (en) 2002-10-09
TR200102713T2 (tr) 2002-05-21
ATE244014T1 (de) 2003-07-15
IL144228A0 (en) 2002-05-23
EP1143994B1 (en) 2003-07-02
ES2202039T3 (es) 2004-04-01
EP1143994A2 (en) 2001-10-17
MXPA01006998A (es) 2002-05-06
AU3083500A (en) 2000-08-01
DE60003632T2 (de) 2004-04-15
IL144228A (en) 2009-06-15
NO20013397D0 (no) 2001-07-09
CA2359392A1 (en) 2000-07-20
US20050271624A1 (en) 2005-12-08
DK1143994T3 (da) 2003-10-20
WO2000041497A3 (en) 2000-09-28

Similar Documents

Publication Publication Date Title
TNSN08064A1 (en) Albumin fusion proteins
AU2002257162A1 (en) Humanized antibodies
WO2005077042A3 (en) Albumin fusion proteins
EP1385545A4 (en) HUMANIZED ANTIBODIES
WO2003060071A3 (en) Albumin fusion proteins
MX2009002816A (es) Proteinas de fusion de albumina.
WO2001079443A3 (en) Albumin fusion proteins
HUP0300369A2 (hu) Többértékű antitestek és alkalmazásuk
ATE403680T1 (de) Herstellung tetravalenter antikörper
NZ502527A (en) Catalytic monoclonal antibodies raised to proteins in aggregated form, and use to treat alzheimers, atherosclerosis, amyloidosis and prions disease
FI963101A (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
WO2007038637A3 (en) Human monoclonal antibodies to cd70
WO2001064889A3 (en) Tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2002018620A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2003033658A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
WO2001098491A3 (en) Osteolevin gene polymorphisms
WO1999028460A3 (en) Molecules interacting with apoptin
NO20013397L (no) Anvendelse av apoptose-induserende midler ved behandling av (auto)immune sykdommer
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
ATE518884T1 (de) Spezifisch an chemokin beta-4 bindende antikörper
IL154298A0 (en) Papap proteins, their preparation and use
MXPA03000979A (es) Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas.
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
EP1161262A4 (en) COLLIGIN / HsP47 WITH SURFACE LOCATION IN CARCINOMA CELLS
EP1475441A3 (fr) Acides nucléiques et polypeptides spécifiques des souches pathogènes du genre Neisseria

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application